ARROWHEAD PHARMACEUTICALS, INC. Equity Securities, FV-NI, Cost
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Equity Securities, FV-NI, Cost of $125.00 million as of 2021-12-31, per its 10-Q filed 2022-02-02.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecuritiesFvNiCost · last filed 2022-02-02
- 2021-12-31: Equity Securities, FV-NI, Cost $125.00M.
- 2021-09-30: Equity Securities, FV-NI, Cost $125.00M.
- 2021-06-30: Equity Securities, FV-NI, Cost $125.00M.
- 2021-03-31: Equity Securities, FV-NI, Cost $125.00M.
| Period end | Equity Securities, FV-NI, Cost |
|---|---|
| 2021-12-31 | $125.00M 10-Q · filed 2022-02-02 |
| 2021-09-30 | $125.00M 10-Q · filed 2022-02-02 |
| 2021-06-30 | $125.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $125.00M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $85.09M 10-Q · filed 2021-02-04 |
| 2020-09-30 | $85.00M 10-K · filed 2021-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |